Kintor Pharmaceutical Ltd. announced its unaudited interim results for the six months ended 30 June 2025. The company reported a significant increase in revenue, climbing from RMB0 million in the first half of 2024 to RMB6.0 million in the same period of 2025. This rise was primarily driven by the global sales of the new high-end cosmetics brand KOSHINÉ's products. However, the company's net loss also increased by RMB11.8 million, or 16.5%, from RMB71.5 million for the six months ended 30 June 2024 to RMB83.3 million for the same period in 2025, mainly due to higher research and development and marketing costs. Marketing expenses surged by RMB6.5 million, or 369.0%, reflecting increased promotional efforts for KOSHINÉ's cosmetics and raw materials business. As of 30 June 2025, Kintor Pharmaceutical Ltd. maintained cash and cash equivalents of RMB52.9 million, along with unutilised bank facilities of RMB30.0 million. The company is executing plans to support the advancement of its clinical trials and R&D, including the Top-up Placing 2025. The Board has decided not to pay any interim dividend for the six months ended 30 June 2025.